



News Release

March 26, 2024

FOR IMMEDIATE RELEASE

Biocure Technology Inc ("CURE") Provides Update on Transaction with Atriva Therapeutics

VANCOUVER, British Columbia, March 26, 2024 -- Biocure Technology Inc. ("CURE" or the "Company") (CSE:CURE) is pleased to provide an update on its previously announced fundamental change transaction (the "Transaction") with Atriva Therapeutics GmbH ("Atriva") (see press release dated September 18, 2023). The Company and Atriva continue to complete their due diligence activities and have agreed to extend the time to complete a definitive agreement in respect of the proposed Transaction from March 31, 2024 to June 30, 2024. The Company's shares will continue to remain halted pending completion of the Transaction.

ON BEHALF OF THE BOARD OF DIRECTORS

/S/ "KONSTANTIN LICHTENWALD"
CFO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7146, or info@biocuretech.com

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.